An exciting candidate therapy for sepsis: Ulinastatin, a urinary protease inhibitor

Intensive Care Medicine

Volumn 40, Issue 8, 2014, Pages 1164-1167

  Linder, Adam ^a   Russell, James A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ULINASTATIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 9A; CATHEPSIN; CHYMOTRYPSIN; ELASTASE; INTERLEUKIN 1; INTERLEUKIN 6; KALLIKREIN; MITOGEN ACTIVATED PROTEIN KINASE; PLASMIN; SERINE PROTEINASE; THROMBIN; TRYPSIN; TUMOR NECROSIS FACTOR ALPHA; GLYCOPROTEIN; TRYPSIN INHIBITOR;

EDITORIAL; HUMAN; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; ACUTE PANCREATITIS; ADULT RESPIRATORY DISTRESS SYNDROME; CELL INFILTRATION; CRITICALLY ILL PATIENT; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENCY; ENZYME RELEASE; INFLAMMATION; INTENSIVE CARE UNIT; MEDIATOR RELEASE; META ANALYSIS (TOPIC); MORTALITY; NEUTROPHIL; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; FEMALE; MALE;

FEMALE; GLYCOPROTEINS; HUMANS; MALE; SEPSIS; TRYPSIN INHIBITORS;

EID: 84904856949     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-014-3366-9     Document Type: Editorial

References (13)

1. Karnad DR, Bhadade R, Verma PK, Moulick ND, Daga MK, Chafekar ND, Iyer S (2014) Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med 40:830-838. doi:10.1007/s00134-014-3278-8
2. Inoue K, Takano H (2010) Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs 19(4):513-520
3. Leng YX, Yang SG, Song YH, Zhu X, Yao GQ (2014) Ulinastatin for acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. World J Crit Care Med 3(1):34-41
4. Smyth E (2003) The trouble with inhibitors. Nature Publishing Group, Horizon Symposia
5. Cooperative Group of Immunomodulatory Therapy of Sepsis, Lin HY (2007) Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with ulinastatin and maipuxin. Zhonghua Yi Xue Za Zhi 87(7):451-457
6. Li Y, Chen H, Li X, Zhou W, He M, Chiriva-Internati M, Wachtel MS, Frezza EE (2009) A new immunomodulatory therapy for severe sepsis: ulinastatin plus thymosin alpha 1. J Intensive Care Med 24(1):47-53
7. Chen H, He MY, Li YM (2009) Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study. Chin Med J 122(8):883-888
8. Su L, Meng FS, Tang YQ, Wen Q, Liu YS, Tang LQ, Duan PK, Luo RJ (2009) Clinical effects of ulinastatin and thymosin alpha1 on immunemodulation in septic patients. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 21(3):147-150
9. Shao YM, Zhang LQ, Deng LH, Yao HG (2005) Clinical study on effects of ulinastatin on patients with systemic inflammatory response syndrome. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 17(4):228-230
10. Wu TJ, Zhang LN, Kang CC (2013) The effect of ulinastatin on disbalance of inflammation and immune status in patients with severe sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 25(4):219-223
11. Moon SW, Lee SW, Hong YS, Park DW, Jang IJ, Yoon YH, Lim SI (2009) The effects of urinary trypsin inhibitor on the outcomes of severe sepsis and septic shock patients. J Korean Soc Emerg Med 20:80-85
12. Opal SM, Lim YP, Siryaporn E, Moldawer LL, Pribble JP, Palardy JE, Souza S (2007) Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: a potential clinical marker and mediator of severe sepsis. Crit Care Med 35(2):387-392 (Pubitemid 46148526)
13. Saigal S, Kapoor G (2014) Ulinastatin: is it worth using in severe sepsis? Intensive Care Med. doi:10.1007/s00134-014-3341-5